





Article abstract—Decrement of the thenar compound muscle action poten-
tials (CMAP), after repetitive nerve stimulation (RNS) of the median nerve at
3 Hz, was evaluated in patients with ALS before riluzole therapy. CMAP size
as well as motor unit number and size estimates were evaluated twice before
and after 1 year of riluzole therapy. The correlation between decrement and
CMAP size reduction per year was highly significant (r  0.77), but no
relationship could be demonstrated between decrement and other variables.
The authors thus propose that decrement after RNS may be used as a predic-
tor of further drop in CMAP size.
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Previous electrophysiologic observations indicate im-
pairment of neuromuscular transmission in patients
with ALS.1-5 Some authors3,5 correlated decremental
responses with the degree of muscle atrophy,
whereas others,1 on the basis of the clinical course,
found that decrement was more pronounced in pa-
tients with rapidly developing motor neuron disease.
Decremental responses have not been correlated
with quantitative parameters that evaluate ALS ac-
tivity. The current prospective study was designed to
analyze the relationship between 1) thenar decre-
ment after slow-rate repetitive nerve stimulation
(RNS) and 2) thenar motor unit loss, average
surface-recorded motor unit action potential (S-
MUAP) size variations and compound muscle action
potential (CMAP) size reduction per year by using
the adapted multiple point stimulation (AMPS)
method in patients with ALS.7
Methods. Participants. Data were collected from 15
consecutive patients with ALS after having obtained their
informed consent; their age ranged from 44 to 71 years
(mean, 57  9). These patients fulfilled the clinical and
electrophysiologic criteria for definite ALS.6 However, dec-
rement with slow-rate RNS greater than 20% was not con-
sidered an exclusion criterion for the diagnosis of ALS.6 All
patients were screened to exclude any additional pathology
affecting peripheral nerves, muscles, or neuromuscular
junctions.
None received drug therapy initially, in particular ri-
luzole. All patients received riluzole after the first electro-
physiologic and clinical evaluation (T0).
The mean disease duration was 24  17 months (range,
6 to 60). At the start of the study, thenar muscle atrophy,
on the side electrophysiologically studied, was absent or
mild in four, moderate in seven, and severe in four pa-
tients. No quantitative strength measurements of thenar
muscles were performed for this study.
Thenar decrement was also studied in a control group of
15 healthy volunteers (age range, 40 to 77 years; mean,
59  15), under identical technical conditions.
Techniques. The stigmatic and reference recording
electrodes consisted of 4 cm long by 0.8 cm wide silver foil.
The stigmatic electrode was positioned transversely over
the thenar eminence, as close as possible to the muscle
endplates. The reference electrode was attached over the
proximal phalanx of the thumb. The ground electrode (sil-
ver foil) was fixed over the dorsum of the wrist (band-pass:
2 Hz to 5 KHz).
All studies were performed on a Nicolet Viking IV EMG
machine (Nicolet Instrument Corp.).
In all 15 patients with ALS, RNS was performed over
the median nerve at the wrist, 7 cm from the stigmatic
electrode. Supramaximal stimuli (150% of the stimulus in-
tensity giving a maximal response) were applied by surface
electrodes (Medelec model LBS 53051; inter-electrode dis-
tance 2.5 cm) in a train of 10 stimuli, 0.2 msec duration, at
a rate of 3 Hz. CMAP decrement was determined as the
difference between the fourth and first motor response
negative peak area and expressed as a percentage. Postex-
ercise exhaustion was not studied.
CMAP size, thenar motor unit number estimate
(MUNE), and average S-MUAP size were measured at the
beginning of the study (T0) and after 1 year of riluzole
therapy (T1). Five patients did not return for the visit at
T1 (two patients died shortly after T0, and three patients
were lost for unknown reasons). The number and size of
thenar motor units were estimated by the AMPS tech-
nique. This method, including its reliability and other ad-
vantages, has been presented in detail in previous
papers.7,8 With AMPS, the mean motor unit size is esti-
mated by collecting and averaging a sample of 10 well-
identified S-MUAP after stimulation at distinct points
along the course of the median nerve between the wrist
and elbow. At each stimulation site, only two or three
S-MUAP are evoked by incremental stimulation (percuta-
neous nerve stimulation, 0.05 msec duration, weak inten-
sity gradually increased by increments of 0.1 to 0.5 mA).
MUNE is obtained by dividing the maximum CMAP size
by the average S-MUAP size.
The hand temperature was maintained above 32 °C for
all measurements.
Results are expressed as mean  1 SD. A log-transform
was applied to decrement to normalize its distribution.
From the University Department of Physical Medicine and Rehabilitation
(Drs. Wang and De Pasqua), Hôpital du Sart Tilman; and the University
Department of Neurology (Drs. Delwaide and Gérard), Hôpital de la Cita-
delle, Liège, Belgium.
Presented in part at the annual meeting of the European Neurological
Society; Jerusalem; June 18–22, 2000.
Received October 19, 2000. Accepted in final form April 5, 2001.
Address correspondence and reprint requests to Dr. F.C. Wang, Depart-
ment of Physical Medicine and Rehabilitation, CHU Sart Tilman B35,
B-4000 Liège Belgium; e-mail: fc.wang@chu.ulg.ac.be
Copyright © 2001 by AAN Enterprises, Inc. 897
Correlation coefficients were computed between variables.
Mean values were compared using Student’s t-test for
paired or unpaired data. All results were considered to be
significant at the 5% critical level (p  0.05). Calculations
were done with SAS (Cary, NC; version 6.12 for Windows)
software.
Results. The mean thenar neuromuscular decrement to
low-rate RNS of the median nerve was 5.8  1.8% (range,
4 through 9) in the control group (n  15), permitting us to
fix the upper normal limit for decrement at the classic
value of 10%. In ALS patients, the mean thenar decrement
was 14.9  10.7%. There was a statistical difference be-
tween both groups (p  0.005). A decremental response
greater than 10% was recorded in 8 (53%) patients with
ALS, and the maximum decrement reached 35%.
The five dropout patients had means of CMAP area,
MUNE, average S-MUAP size, and thenar decrement at
T0 not different from means of the 10 patients who were
subsequently studied (CMAP area: p  0.95, MUNE: p 
0.73, average S-MUAP size: p  0.61, thenar decrement:
p  0.64)
In ALS patients, the mean thenar MUNE measured by
AMPS dropped from 39.8  27.1 at T0 to 18.6  19.3 at T1
(p  0.002) (versus 263  117 in normal subjects8). The
mean motor unit loss per year was 56  24% (range, 27 to
99), and no correlation could be demonstrated with the
decrement (r  0.57; p  0.08) (figure 1A).
The mean average S-MUAP size (n  10) increased
from 335  195 V.ms at baseline T0 to 417  653 V.ms
at T1 (p  0.66) (versus 94.1  30.3 in normal subjects8).
The mean of individual average S-MUAP size variations
per year was 1.3  77% (range: 78 to 170). There was
no correlation between the average S-MUAP size varia-
tion per year and the decrement (r  0.48; p  0.16)
(figure 1B).
The mean thenar CMAP size (n  10) dropped from
10.8  6.9 mV.ms at T0 to 5.2  5.4 mV/ms at T1 (p 
0.001) (versus 21.9  7.7 mV/ms in normal subjects8). The
mean CMAP size reduction per year was 57  29% (range,
10 to 99). A correlation (r  0.77; p  0.01) was found
between the decrement and CMAP size reduction per year
(figure 2).
Discussion. Decremental motor responses to slow-
rate RNS in patients with ALS were initially de-
scribed by Mulder, Lambert, and Eaton in 1959.5
Later, other studies reported similar findings.1-4 In
one of them,3 the decrement was larger and present
more often in muscles showing atrophy. In another
one,1 decrement was found predominantly in pa-
tients with rapidly developing symptoms, suggesting
that decrement reflects activity or rate of progression
of the motor neuron disease. The current study
confirms previous electrophysiologic observations in-
dicating that impairment of neuromuscular trans-
mission is not an uncommon feature in ALS. In fact,
53% of patients with ALS had thenar decrement
greater than the classic limit of 10% with a maxi-
mum value of 35%. These data suggest that more
than 20% decrement with slow-rate RNS should not
be an exclusion criterion for ALS diagnosis as pro-
posed by Brooks.6
Thenar decrement (before riluzole therapy), the-
nar motor unit loss, CMAP, and average S-MUAP
size variations per year (on the basis of two measure-
ments before and after 1 year riluzole therapy) were
evaluated in 10 ALS patients. RNS was only per-
Figure 1. Relationship between thenar decrement and (A)
motor unit loss per year and (B) average surface-recorded
motor unit action potential (S-MUAP) size variation per
year in 10 patients with ALS.
Figure 2. Relationship between thenar decrement and
compound muscle action potential (CMAP) reduction per
year in 10 patients with ALS.
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formed before therapy to avoid a possible influence of
riluzole on decrement. Myasthenia is reported as an
adverse effect of riluzole by the manufacturer and in
one recent observation.9 The correlation between dec-
rement and CMAP size reduction per year was
highly significant (figure 2), but the decrement was
neither significantly correlated with the motor unit
loss nor with the average S-MUAP size variation per
year (figure 1). We thus suggest that the percentage
of decrement after slow-rate RNS might be inter-
preted as a predictor of further drop in CMAP size.
The greater the decrement, the greater the subse-
quent drop in CMAP size.
This result might be considered paradoxical. In
fact, because a drop in CMAP size is the product of
motor unit loss and average S-MUAP size variation,
why were these parameters not correlated with dec-
rement? Motor unit loss is the primary pathologic
process in ALS and cannot by itself explain decre-
mental motor responses of the remaining motor
units. The average S-MUAP size results from the
interaction of at least three distinct processes: motor
unit loss, collateral reinnervation, and motor unit
degeneration. One or more of these processes could
explain pathologic decrements in ALS, but their role
might be concealed within the average S-MUAP size
parameter because these three processes influence
the motor unit size in different ways: 1) Preferential
loss of large or small units induces either an average
S-MUAP size decrease or increase. This size effect
derived from the motor unit loss is unlikely to ex-
plain the decremental responses. 2) In ALS, the mo-
tor unit size increases by collateral reinnervation.10
If reinnervation is the required substrate for decre-
ment, the greatest chance to see it should be in
larger reinnervated motor units. However, this
seems not to be the case. In fact, a study of neuro-
muscular transmission in isolated motor unit poten-
tials (MUP) indicates that decrements were more
frequent and severe in small MUP.2 Another expla-
nation should be emphasized, however. In acute
forms of ALS, short survival times of reinnervated
motor units might prevent full reinnervation matu-
ration and enlargement of motor unit size. Thus, a
high degree of reinnervation immaturity, with re-
duced safety factor at immature reinnervated end-
plates and intermittent axonal conduction blocks at
newly formed nerve endings, might be an explana-
tion for decremental motor responses. 3) At advanced
stages of the disease, motor units may undergo de-
generation with a decrease in their size. Based on
the observation that decrement was found more fre-
quently and with more severity in small MUP, it
may be suggested that synaptic transmission failure
at neuromuscular junctions undergoing degeneration
is probably an important factor accounting for the
decrements.2
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